Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
68,524
Sort by:
Leiomyosarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
557 pages
Anal Cancer - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
525 pages
Fibrosarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Fibrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
120 pages
Optic Neuropathy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
70 pages
Synovial Sarcoma - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
359 pages
Becker Muscular Dystrophy - Pipeline Review, H1 2020
US$ 2,000.00
... . The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
75 pages
Meniere Disease - Pipeline Review, H1 2020
US$ 2,000.00
... . The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development ...
February 2020
49 pages
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2020
US$ 2,000.00
... The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under ...
February 2020
75 pages
Primary Immune Deficiency (PID) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
125 pages
Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
623 pages
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020
US$ 2,000.00
... . The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
156 pages
Complex Regional Pain Syndrome - Pipeline Review, H1 2020
US$ 2,000.00
... . The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Complex Regional Pain Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development ...
February 2020
60 pages
Crigler-Najjar Syndrome - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
38 pages
Familial Adenomatous Polyposis - Pipeline Review, H1 2020
US$ 2,000.00
... . The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
69 pages
Osteogenesis Imperfecta - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
63 pages
Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2020
US$ 2,000.00
... pipeline guide Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders), complete with analysis by stage of development ...
February 2020
44 pages
Coccidioidomycosis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Coccidioidomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Coccidioidomycosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
76 pages
Contrast Induced Nephropathy - Pipeline Review, H1 2020
US$ 2,000.00
... Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
45 pages
Osteomyelitis - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
49 pages
Ragweed Pollen Allergy - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
35 pages
Bone Marrow Transplant Rejection - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
751 pages
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020
US$ 2,000.00
... . The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
78 pages
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
February 2020
880 pages
Pressure Ulcers - Pipeline Review, H1 2020
US$ 2,000.00
... releases. The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
February 2020
32 pages
Alpha L-Iduronidase - Pipeline Review, H1 2020
US$ 3,500.00
Alpha L-Iduronidase - Pipeline Review, H1 2020 SUMMARY Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are develo...
February 2020
64 pages
Apoptosis Regulator BAX - Pipeline Review, H1 2020
US$ 3,500.00
Apoptosis Regulator BAX - Pipeline Review, H1 2020 SUMMARY Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 7 molecules. Out of which approximatel...
February 2020
47 pages
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020
US$ 3,500.00
Bromodomain Containing Protein 2 - Pipeline Review, H1 2020 SUMMARY Bromodomain Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing protein 2 is...
February 2020
70 pages
Bromodomain Containing Protein 3 - Pipeline Review, H1 2020
US$ 3,500.00
Bromodomain Containing Protein 3 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Bromodomain Containing Protein 3 - Pipeline Review, H1 2020'; Bromodomain Containing P...
February 2020
69 pages
Cell Division Protein FtsZ - Pipeline Review, H1 2020
US$ 3,500.00
Cell Division Protein FtsZ - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2020'; Cell Division Protein FtsZ (f...
February 2020
34 pages
Dystrophin - Pipeline Review, H1 2020
US$ 3,500.00
Dystrophin - Pipeline Review, H1 2020 SUMMARY Dystrophin (DMD) pipeline Target constitutes close to 49 molecules. Out of which approximately 43 molecules are developed by companies and remaining by...
February 2020
122 pages
E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020
US$ 3,500.00
E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020 SUMMARY E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6....
February 2020
101 pages
Endoplasmin - Pipeline Review, H1 2020
US$ 3,500.00
Endoplasmin - Pipeline Review, H1 2020 SUMMARY Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Hea...
February 2020
52 pages
Exportin 1 - Pipeline Review, H1 2020
US$ 3,500.00
Exportin 1 - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Exportin 1 - Pipeline Review, H1 2020'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)...
February 2020
107 pages
Frataxin Mitochondrial - Pipeline Review, H1 2020
US$ 3,500.00
Frataxin Mitochondrial - Pipeline Review, H1 2020 SUMMARY Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 14 molecules. Out of which app...
February 2020
55 pages
Galectin 3 - Pipeline Review, H1 2020
US$ 3,500.00
Galectin 3 - Pipeline Review, H1 2020 SUMMARY Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Lam...
February 2020
81 pages
Iduronate 2 Sulfatase - Pipeline Review, H1 2020
US$ 3,500.00
Iduronate 2 Sulfatase - Pipeline Review, H1 2020 SUMMARY Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase...
February 2020
64 pages
Leukotriene A 4 Hydrolase - Pipeline Review, H1 2020
US$ 3,500.00
Leukotriene A 4 Hydrolase - Pipeline Review, H1 2020 SUMMARY According to the recently published report 'Leukotriene A 4 Hydrolase - Pipeline Review, H1 2020'; Leukotriene A 4 Hydrolase (LTA 4 Hydro...
February 2020
50 pages
